Successful applications to date for access to the free TRANSVAC services

Access to the free TRANSVAC services has been approved by the Scientific Advisory Committee and the User Selection Panel for the following projects:
Results of the first call for applications (1101-1)
Results of the second call for applications (1104-2) 
Results of the third call for applications (1107-3)

Results of the fourth call for applications (1110-4)
Results of the fifth call for applications (1201-5)
Results of the sixth call for applications (1204-6) 
Results of the seventh call for applications (1207-7)  
Results of the eighth call for applications (1210-8) 
Results of the ninth call for applications (1301-9) 
Results of the tenth call for applications (1304-10)

Results of the first call for applications (1101-1)

Applicant / User Access granted to Access units provided Project
 1    Statens Serum Institut (SSI), Copenhagen, Denmark
Prof. Peter Andersen
Experimental Non-human primate model facility,
Biomedical Primate Research Centre, The Netherlands
20 CD4/8 responses by CAF
Evaluation of the immunogenicity and tolerability of an antigenic formulation in CD4 T-cell inducing CAF01 and CD4/CD8 T-cell inducing CAF05 adjuvant upon simultaneous muco-parenteral compared to traditional parenteral delivery in rhesus macaques
 2  Themis Bioscience, Vienna, Austria
Dr. Katrin Ramsauer
ILLUMINA Deep Sequencing,
Helmholtz Centre for Infection Research, Germany
6 MVDVAX
A single tetravalent live attenuated recombinant Measles Virus Vaccine against DENGUE
 3 Université de Lyon, Faculté de Médecine Saint Etienne, Lyon, France
Dr. Stéphane Paul
Vaccine formulation laboratory
World Health Organization Collaborating Centre - University of Lausanne, Switzerland
9 MUCOSTIM
Evaluation of adjuvant formulation in the induction of mucosal immune responses against HIV after subcutaneous or intramuscular vaccination with p24 antigen encoated on PLA particles
 4

Trinity College, Dublin, Ireland
Dr. Karen Misstear

Vaccine formulation laboratory,
World Health Organization Collaborating Centre - University of Lausanne, Switzerland
5

TARGET-PART-QS21
Development of potent mucosal vaccines by combining an effective targeting agent with immunostiumlatory particulate adjuvants

K. Misstear et al., Targeted nasal vaccination provides antibody independent protection against Staphylococcus aureus, The Journal of Infectious Diseases (2013), in press.

 

Results of the second call for applications (1104-2)

  Applicant / User
Access granted to Access units provided Project
 5 INSERM, Institut Pasteur de Lille, Lille, France
Dr. Jean-Claude Sirard 
AGILENT Microarrays,Max Planck Institute for Infection Biology, Germany 2 FLAGMARK
Transcriptional analysis of flagellin-mediated adjuvant activity: defining predictive biomarkers of efficacy in blood samples
 6 The Jenner Institute, Oxford, United Kingdom
Prof. Adrian Hill
Vaccine formulation laboratory,World Health Organization Collaborating Centre - University of Lausanne, Switzerland 5 CombiVAX
Combination (vector-adjuvant-protein) vaccine against malaria
 7  University College Cork, Cork, Ireland
Dr. Anne Moore
Large Animal studies,Central Veterinary Institute of Wageningen, The Netherlands 431 ImmuPatch
Pre-clinical Testing of Influenza Vaccine Incorporated in Dissolvable ImmuPatch Microneedle Arrays

 

Results of the third call for applications (1107-3)

 

Applicant / User Access granted to Access units provided Project
 8  Academy of Sciences of Czech Republic, Ceske Budejovice, Czech Republic
Dr. Michail Kotsyfakis
ILLUMINA Deep Sequencing, Helmholtz Centre for Infection Research, Germany 60 DUALVACANTIRICINUS
The discovery of candidate 'dual' antigens for vaccine development by deep sequencing of Ixodes ricinus salivary and midgut transcriptomes
 9 Glycovaxyn, Schlieren, Switzerland
Dr. Gerd Lipowsky
Experimental murine validation platform,Helmholtz Centre for Infection Research, Germany 1 GVXN Pn4-EPA_1
Evaluation of the immunogenicity and functionality of a glycoprotein vaccine against Streptococcus pneumoniae serotype 4
 10 Institute of Immunology Inc. Zagreb, Zagreb, Croatia
Dr. Jelena Ivancic-Jelecki
ILLUMINA Deep Sequencing, Helmholtz Centre for Infection Research, Germany 36 MUMPSVAC
The influence of viral population diversity on safety and immunogenicity of licensed mumps vaccine strain
 11 Biomedical Primate Research Centre, Rijswijk, The Netherlands
Dr. Ed Remarque
Vaccine formulation laboratory, World Health Organization Collaborating Centre - University of Lausanne, Switzerland 9 rAMA1_VAC
Formulation of model vaccines for the PHARVAT adjuvant harmonization platform


Results of the fourth call for applications (1110-4)

No successful application.


Results of the fifth call for applications (1201-5)

  Applicant / User
Access granted to Access units provided Project
 12  Animal Health and Veterinary Laboratory Agency,New Haw, United Kingdom
Dr. Bernardo Villarreal-Ramos
ILLUMINA Deep Sequencing, Helmholtz Centre for Infection Research, Germany 30 RNA seq in bovine
TBRNA sequencing for the discovery of potential biomarkers of disease/protection in bovine TB and their potential use as model for TB in humans
 13 University of Zaragoza,Zaragoza, Spain
Prof. Carlos Martin
AGILENT Microarrays,Max Planck Institute for Infection Biology, Germany 8 MTBVAC-TS
MTBVAC transcriptional signature of phase I BCG/MTBVAC-vaccinated subjects

 

Results of the sixth call for applications (1204-6)

Applicant / User Access granted to Access units provided Project
 14    Scientific Insitute of Public Health,
Brussels,Belgium
Dr. Kris Huygen
Large Animal studies,
Central Veterinary Institute of Wageningen, The Netherlands
302 BCG-p85A-combo
Increasing the protective efficacy of  M. bovis BCG vaccine by combined vaccination with plasmid DNA encoding the mycolyl-transferase Ag85A (Rv3804c).
15 INSERM,
Lille, France
Dr. Jean-Claude Sirard
Vaccine formulation laboratory
World Health Organization Collaborating Centre - University of Lausanne, Switzerland
14 FLAGTRIAL
From mice to appropriate model of human intradermal immunization: efficacy and signature of the TLR5 agonist flagellin in Sus scrofa pigs
16 INSERM,
Lille, France
Dr. Jean-Claude Sirard
Large Animal studies,
Central Veterinary Institute of Wageningen, The Netherlands
562 FLAGTRIAL
From mice to appropriate model of human intradermal immunization: efficacy and signature of the TLR5 agonist flagellin in Sus scrofa pigs
17 INSERM,
Lille, France
Dr. Jean-Claude Sirard
AGILENT Microarrays,
Max Planck Institute for Infection Biology, Germany
1 FLAGTRIAL
From mice to appropriate model of human intradermal immunization: efficacy and signature of the TLR5 agonist flagellin in Sus scrofa pigs
18 Medical Research Council Clinical Trials Unit,
London, United Kingdom
Dr. Sarah Joseph
ILLUMINA Deep Sequencing,
Helmholtz Centre for Infection Research, Germany
14 HIV_vaccine_breakthrough
Pilot study to deep sequence HIV breakthrough infections that have occurred during HIV vaccine trials conducted by the TaMoVac consortium and partner institutions

 

Results of the seventh call for applications (1207-7)

Applicant / User Access granted to Access units provided Project
 19  Barcelona Centre for International Health Research, Barcelona, Spain
Dr. Carlota Dobano Lázaro
AFFYMETRIX Microarrays,
University of Regensburg, Germany
3 BACHMI01_VacGeneExp
Controlled human malarial infection: a tool to identify key immunological responses and new antigens for vaccine development
20 INSERM,
Lille, France
Dr. Camille Locht
AGILENT Microarrays,
Max Planck Institute for Infection Biology, Germany
3

BPZE1-Immuntranscript
Transcriptional analysis of BPZE1-induced immunity

21

Statens Serum Institut, Copenhagen, Denmark
Dr. Dennis Christensen

Stable Reference Reagents, Health Protection Agency, National Institute for Biological Standards and Control, UK

44

CD4-8 resp by CAF
Evaluation of the immunogenicity and tolerability of an antigenic formulation in CD4 T-cell inducing CAF01 and CD4/CD8 T-cell inducing CAF09 adjuvant upon nasal or intramuscular delivery in rhesus macaques

22

Institute of Pharmacology and Structural Biology/CNRS, Toulouse, France
Mrs Martine Gilleron

Vaccine formulation laboratory
World Health Organization Collaborating Centre - University of Lausanne, Switzerland
8 LipTBvaccine
Improving the stability of DDA liposomes to deliver lipid antigens
23

Poznan University School of Medical Science, Poznan, Poland
Prof. Andrzej MACKIEWICZ

AFFYMETRIX Microarrays,
University of Regensburg, Germany
1 TRANSMELVAX
Transcriptom analysis of gene modified therapeutic melanoma cellular vaccine

 

Results of the eighth call for applications (1210-8)

Applicant / User Access granted to Access units provided Project
24 Statens Serum Institut, Copenhagen, Denmark
Dr. Dennis Christensen
AFFYMETRIX Microarrays,
University of Regensburg, Germany
3 Transc-rep-prof-by-CAF
Transcriptional response profiles in cynomolgus macaques upon CAF01- or CAF09-formulated parenteral and mucoparenteral vaccination
25

Centro Nacional de Biotecnología, Madrid, Spain
Prof. Mariano Esteban Rodríguez

Rhesus Macaque Models, Health Protection Agency, Centre for Emergency Preparedness and Response, UK 2 C6LVAC
Immunogenicity of an HIV/AIDS vaccine candidate lacking vaccinia virus gene C6L in non-human primates

 

Results of the ninth call for applications (1301-9)

No successful application.

Results of the tenth call for applications (1304-10)

Applicant / User Access granted to Access units provided Project

26

INSERM, Lille, France
Dr. Camille Locht

AFFYMETRIX Microarrays,
University of Regensburg, Germany

5

BPVACtranscriptome
Transcriptional analysis of human subjects nasally vaccinated with live attenuated B. pertussis BPZE1

27

King's College London, London, United Kingdom
Dr. Sandra Diebold

AFFYMETRIX Microarrays,
University of Regensburg, Germany

2

Ovarian Carcinoma & TLR7
Understanding the immunosuppressive tumour environment for induction of anti-tumour immunity using TLR7 agonists

28

University of Amsterdam, Amsterdam, The Netherlands
Dr. William Paxton

Stable Reference Reagents, Health Protection Agency, National Institute for Biological Standards and Control, UK

20

HEAM
HIV-1 Envelopes Associated with MTCT

29

Crucell, Leiden, The Netherlands
Dr. Jenny Hendriks

Stable Reference Reagents, Health Protection Agency, National Institute for Biological Standards and Control, UK

100

CMIforTBAd-vacc
Standardization of CMI assessment by flow cytometry for the development of Adeno-based TB vaccine candidate